The 6th joint national committee report (JNC-6): new guidelines for hypertension therapy from the USA.

This manuscript will highlight the major elements of the recently published sixth Joint National Committee (JNC-6) report. First, a 3-tiered classification of overall cardiovascular risk is provided as a guide to the institution of therapy with either lifestyle modifications or antihypertensive drugs. Second, the need for prevention is stressed. Third, guidelines for the effective use of appropriate lifestyle modifications are provided. Fourth, a 3-pronged pathway for the choice of critical therapy is provided: one for uncomplicated hypertensive; another for those with "compelling" indications for specific drugs, including the presence of diabetic nephropathy, congestive heart failure, post-myocardial infarction or systolic hypertension in the elderly; the third for those with concomitant conditions that may be either favorably or unfavorably affected by specific types of drugs. In addition, the report emphasizes the need to achieve the goal of less than 140/90 mmHg by a progressive process of therapy and, if necessary, referral to a hypertension specialist. Recommendations are made for improved adherence to therapy, therapy of resistant hypertension and hypertensive crises.

[1]  Eter,et al.  EFFECT OF AMLODIPINE ON MORBIDITY AND MORTALITY IN SEVERE CHRONIC HEART FAILURE , 2000 .

[2]  P. Whelton,et al.  Risk of End-stage Renal Disease in Diabetes Mellitus: A Prospective Cohort Study of Men Screened for MRFIT , 1997 .

[3]  Alan D. Lopez,et al.  Alcohol consumption and mortality among middle-aged and elderly U.S. adults. , 1997, The New England journal of medicine.

[4]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[5]  J. Cohn,et al.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. , 1997, Circulation.

[6]  J. Cutler,et al.  Randomized trials of sodium reduction: an overview. , 1997, The American journal of clinical nutrition.

[7]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[8]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[9]  G. MacGregor,et al.  Salt—more adverse effects , 1996, The Lancet.

[10]  W. Kannel Blood pressure as a cardiovascular risk factor: prevention and treatment. , 1996, JAMA.

[11]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.

[12]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[13]  J. Laragh,et al.  Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. , 1995, Hypertension.

[14]  R. Vandongen,et al.  Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. , 1992, Hypertension.